FDA panel: Benefit of Baxter's immune therapy outweighs risk

Thu Jul 31, 2014 1:31pm EDT

Related Topics

(Reuters) - The benefits associated with Baxter International Inc's experimental treatment for certain diseases of the immune system outweigh the risks, an advisory committee to the U.S. Food and Drug Administration concluded on Thursday, paving the way for approval of the therapy.

The panel voted 15-1 that the available data show a favorable benefit to risk ratio for treatment, HyQvia, which is designed to treat primary immunodeficiency diseases.

These are genetic disorders in which certain cells of the immune system are missing, leading to a infections, recurrent pneumonia and abscesses of the organs.

The FDA is not obliged to follow the advice of its advisory panels but typically does so.

(Reporting by Toni Clarke in Washington; Editing by Bill Trott)

FILED UNDER:
A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article